UPDATE 4-AstraZeneca sees higher 2022 sales even as COVID boost wanes
* Quarterly results top expectations, dividend raised* Shares among top FTSE 100 gainers* Overall 2022 revenue to rise, but COVID-sales will fall* Vaccine sales drop to be offset by antibody drug (Adds CEO comment on vaccine)By Pushkala Aripaka and ...
Read more